Context: Patients with Turner syndrome (TS) are at risk for osteoporotic fractures.
T urner syndrome (TS) is mainly characterized by short stature as a result of the lower-leg growth reduction and by amenorrhea as a result of the lack of ovarian hormone production. Among other symptoms, individuals may be relatively inconspicuous by presenting with recurrent otitis media (1); however, some may develop life-threatening aortic dissection (2) . TS affects 1:2000 live-born females (3) , and the symptoms are caused by the loss of the short arm of the X chromosome.
The first systematic search for associations of different medical conditions with TS was performed in Denmark, based on the national registry for hospitalized patients (4) . From this study, it was determined that fractures occur twice as frequently in females with TS as they do in the general population. A higher fracture rate in patients with TS was later confirmed by a different approach consisting of a nationwide questionnaire survey, where the fracture frequency was increased by 25% in TS patients and the mean fracture-free survival was 10 years shorter than that of the general population (5) .
Increased bone fragility in patients with TS was seemingly and reasonably explained by the lack of estrogen production, which could lead to a low bone mass. Low bone mineral density (BMD), in association with estrogen insufficiency, was indeed reported in patients with TS in several studies (6, 7) . However, other studies showed a normal BMD in TS, especially when the short stature of these patients was considered, and estrogens were substituted (8, 9) .
Parameters other than BMD, such as bone geometry measures, also contribute to whole bone strength. Enlarged width and decreased cortical thickness at the radius were reported in girls and young adult females with TS (10, 11) . This skeletal phenotype is estrogen independent and is probably caused by the deletion of the short stature homeobox gene, as this feature is shared among patients with TS and patients with isolated short stature homeobox deficiency (12) .
Despite all of the previous studies, the age-controlled, time-controlled, and region-controlled prospective fracture incidence among pediatric patients with TS is not known, and the long-term development of volumetric BMD (vBMD) and other geometry-based bonestrength indices has not been previously described in this condition.
The aims of this study were the following: (1) to determine whether fracture incidence is increased in girls with TS during their growth, while getting growth hormone (GH) and if needed, estrogens, compared with that in the general female population and (2) to search for associations with the development of BMD and bone strength over a 6-year period.
Subjects and Methods

Patients
This was a prospective, single university hospital referral center study conducted between January 2008 and September 2014. We asked all prepubertal and pubertal patients with TS (n = 47) participating in our previously published cross-sectional peripheral quantitative computerized tomography (pQCT) study (11) to continue in a long-term follow-up. All of the girls (and their parents) consented, but some dropped out as a result of transition to adult care (n = 9), recognition of another disease(s) affecting the bone metabolism (13 Crohn's disease, 13 primary ciliary dyskinesia with bronchiectasis), or relocation (n = 4). The assessments were made 2, 4, and 6 years after the initial bone scan. Patients were included when bone scans were available for at least three of the four study time points (28 girls) or at the study start and end time points (four girls). Therefore, the final analyses were conducted in 32 patients.
The TS diagnosis was confirmed by genetic testing in all participants. Their karyotypes were X monosomy (n = 15), the 45,X/46,XX mosaicism (n = 2), other double or triple cell-line mosaics with at least two aberrant cell lines (n = 10), or there was a structural defect in one X chromosome (two deletions, one isochromosome, and two translocations).
At the study start, there were 15 prepubertal (Tanner stage I breast development), 14 pubertal premenarcheal, and three postmenarcheal TS girls. The body height was measured with a stadiometer to the nearest 1 mm. Weight was measured with an electronic scale to the nearest 100 g. Body mass index was calculated as the weight (kilograms) divided by the square of the height (meters). Height, weight, and body mass index Z-scores were calculated using the most recent national reference data (13) . The forearm length Z-scores were calculated based on data from a previously published pQCT study (14) .
Hormonal therapy
All of the girls with TS were treated with recombinant human GH at a median dose of 50 mg/kg/day; the dose has been adjusted according to body weight at each of the subsequent visits at the out-patient clinic (15) . Three postmenarcheal girls finished their GH therapy ,8 months before the first densitometry assessment. The GH therapy was completed when the near-final height was achieved (i.e., growth velocity ,2 cm/year estimated from a period of 6 months or more).
Six patients developed spontaneous puberty, whereas 24 and two girls with primary and secondary amenorrhea, respectively, were supplemented with oral estradiol (17-b estradiol) pills to induce/complete their pubertal development. The scheme was based on a low starting dose, which was gradually increased, as described previously in detail (11) . All but three girls started menstruating during the 6-year follow-up study.
Thyroxine substitution was necessary in eight patients with autoimmune thyroid disease and one patient after total thyroidectomy as a result of a suspect fine-needle aspiration biopsy obtained from a thyroid nodule. All of these patients had been euthyroid over the study duration.
Fracture incidence and comparison with the healthy population
Fractures were ascertained through a simple questionnaire focused on age, site, and the mechanism of injury. The fracture history was taken at the time of first densitometry (prevalent fractures) and then at every subsequent visit (incident fractures). The fractures were verified through X-rays. Clinically significant fractures, as defined by the International Society for Clinical Densitometry (16) , were included in the following analyses. The age-stratified national female population counts and the age-stratified numbers of females hospitalized with a clinically significant fracture (and no other reported diagnosis) were obtained from the Institute of Health Information and Statistics through the National Register of Hospitalised Patients for every year between 2008 and 2014 (www.uzis.cz/en/ registers/national-health-registers/nr-hospitalised-patients). Because there was no possibility to gain age-stratified data on outpatient-treated females with fractures at the national level, for reference, we used the age-stratified numbers of females who attended the Emergency Department of Motol university hospital (with 2200 beds as the biggest in the country) because of trauma, resulting in the fracture of the limbs or spine (and no other diagnosis), in every year between 2008 and 2014. We also registered whether they were hospitalized.
Control group for pQCT-derived bone parameters
The control group consisted of 185 healthy girls who had been included in the Dortmund Nutritional and Anthropometric Longitudinally Designed Study, performed at the Research Institute for Child Nutrition in Dortmund, Germany (17) . This was an observational study investigating the interrelations of nutrition, growth, and metabolism in healthy children. The cohort was recruited in a representative sample of school children of Dortmund that was mostly composed of middle-class families, and all participants were of white race. The age-specific reference values for bone density and geometry parameters in this population were already published (18, 19) . For this particular study, the original data from healthy girls were used to create height-specific smooth reference curves for all of the relevant bone parameters.
Ethical considerations
The current study was approved by the institutional Ethics Committee and conformed to the Declaration of Helsinki. All of the participants included in this study (or a parent if the patient was younger than 18 years) consented to the testing.
Bone strength assessment
An XCT 2000 scanner (StratecMedizintechnik, Pforzheim, Germany) was used to obtain measurements at the nondominant radius. The dominancy was determined according to handedness. A single tomographic 2.0 mm-thick slice was taken at distances corresponding to the 4% and 65% bone lengths, as measured from the styloid process to the olecranon of the ulna. A voxel size of 0.5 3 0.5 3 2.0 mm was used. The images were processed, and the numerical values were calculated using version 6.20 C of the integrated XCT software. At the distal radius (4% site), the total bone mineral content, total bone cross-sectional area (CSA), and trabecular vBMD were measured through the CBD function, C1/P1 mode, and threshold of 280 mg/cm 3 . The trabecular bone compartment was assumed to be represented by the inner 45% of the total bone CSA. The polar strength-strain index (SSI polar) was determined using a function SSI, separation mode one, and threshold of 280 mg/ cm 3 . At the proximal radius (65% site), the total bone mineral content and total bone CSA were measured through the CBD function, C1/P1 mode, and threshold of 280 mg/cm 3 . The cortical bone CSA and cortical vBMD were assessed through the CORTBD function, separation mode one, and threshold of 710 mg/cm 3 . Cortical vBMD was then adjusted for the partial volume effect by an algorithm suggested by Rittweger et al. (20) and previously described in detail (21) . The relative cortical bone CSA was calculated as the ratio between the cortical bone CSA and total bone CSA and expressed in percent (i.e., multiplied by a factor of 100). The cortical thickness was calculated as a difference between the total bone radius and marrow bone radius using the following formula: (total bone CSA/p) 0.5 -[(total bone CSA -cortical bone CSA)/p] 0.5 . The SSI polar was determined by using the SSI function, separation mode one, and threshold of 480 mg/cm 3 . The precision errors of the pQCT measures were reported to be low at the radius (11).
Biochemistry
The blood samples were obtained from the patients on the day of the bone assessment and were a part of their regular follow-up. Serum follicle-stimulating hormone (FSH) levels were measured in Motol University Hospital's accredited laboratory by a chemiluminescence immunoassay; the results are given in international units per liter. The intraindividual coefficient of variation for the kit was 11%.
Statistical analyses
The statistical computing environment R was used to conduct all of the statistical analyses (22) (23) (24) . The data are reported as the means [standard deviation (SD)] unless specified otherwise. The height-specific Z-scores for the pQCT-derived bone parameters were established in the same way as we did previously for the muscle functions (25) using Cole's LMS method (26) : in summary, parameters L (the power in the Box-Cox transformation), M (the median), and S (the generalized coefficient of variation) are fitted in the formula to transform the raw data (X) into Z-scores (Z): Z = ln(X/M)/S if L = 0 and Z = (X/M 2 1)/S if L = 1. The mean Z-scores were tested for the difference from zero using the one-sample t test.
To evaluate the age-dependent changes in individual pQCTderived bone parameters, a cubic regression model with a random intercept was used for each variable. More precisely, the formula for jth observation of ith girl is
where h i ; N(0, s h 2 ) is the random effect of the ith subject, and « ij ; N(0, s 2 ) is the random error. Pointwise confidence intervals for the population means are based on the asymptotic normality of the maximum likelihood estimators.
The same model was used to assess the impact of the hormonal treatment and fracture history on the bone parameters by adding the duration of GH treatment and estrogen substitution, respectively, or positive fracture history as the next explanatory variable. The FSH serum concentration at the study end was also added as an independent explanatory variable.
Age-stratified national annual fracture incidence in healthy girls and female adolescents aged 0 to 18 years was estimated as a ratio of the incidence of hospitalized healthy girls with a fracture in the country to the percentage of healthy girls with a fracture that were hospitalized within Motol University Hospital. First, we obtained a downward-biased estimate of the agedependent, 6-year incidence rate for each healthy girl in our dataset by determining the maximum of the corresponding fracture rates. The estimated 6-year fracture incidence in the healthy population of the same age structure (which is representative of our group of girls with TS) was then compared with the observed 6-year fracture incidence in TS, with the P value calculated by the Monte Carlo simulation.
Results
The mean basic anthropometric measures and the selection of the treatment-related clinical data of the girls with TS are shown in Table 1 . Whereas the body height of the patients was decreased compared with the healthy controls, regardless of their pubertal stage, their forearms were even shorter when comparing them with those of healthy girls of the same height. There was no difference in the age of the recombinant human GH treatment initiation [P = 0.156, analysis of variance (ANOVA) test], estrogen substitution initiation (P = 0.366, ANOVA test), or age at menarche among the three groups (P = 0.196, ANOVA test).
Comparison of the fracture rate in girls with TS and healthy girls
There were three of 32 girls with TS who had a new, clinically significant fracture during the 6-year observation study. One girl broke her left tibia while falling down the stairs (at age 14.5 years), another girl sustained a left forearm fracture during skating (at age 12.8 years), and the third girl had a fracture of the right humerus (fall on ice, age 11.5 years) and left distal forearm (fall from a bike, age 11.9 years). The humerus and forearm fractures affected the shafts of the bones. On the national level, there were between 43.509 and 66.342 girls (mean 6 SD 51.475 6 6.829 girls) for every 1-year category (0 to 20 years) and every year (2008 to 2014). The number of girls hospitalized with either a limb or spine fracture varied between 1756 and 2122 per year (mean 6 SD 1953 6 130 girls per year). The most frequent diagnosis was a forearm fracture. The national incidence of hospitalized girls with a limb or spine fracture was calculated for every year of observation and then averaged. More than 9000 girls (9263), aged 0 to 18 years, attended Motol University Hospital because of the limb or spine fracture between 2008 and 2014, and only 354 (3.8%) were hospitalized. The ratio of the national incidence of hospitalized girls with a fracture to a singlecenter proportion of hospitalized girls with a fracture was calculated to estimate the specific fracture rate in "otherwise healthy" girls on the country level. The peak incidence occurred at 11 years and reached 12.5% (Fig. 1) . From these data, we estimated the downward-biased, agedependent, 6-year fracture rate for each healthy girl in our dataset by determining the maximum of the corresponding annual fracture rates. Then, in a subgroup of all healthy girls of the same age as that of our girls with TS, we report the probability of one to 10 girls with fractures ( Table 2) . As the fracture rate in our girls with TS was not significantly higher compared with the downward-biased fracture rate estimate in healthy girls (P = 0.48), it cannot be higher than the real fracture incidence in healthy girls.
The development of bone parameters during growth in TS
The pQCT-derived bone density and strength parameters at the study beginning and end time points are summarized in Table 3 . In addition to the raw data and height-specific Z-scores, we report the 95% confidence intervals for the least significant changes of each pQCT measure. The age-specific, cubic regression model-based TS population means with pointwise confidence intervals for height Z-scores for forearm length and selected pQCT parameters are depicted in Figs. 2 and 3 , respectively. These figures illustrate the estimated development of anthropometric and bone parameters in girls with TS, as calculated from our individual longitudinal data collection. Even though trabecular vBMD was normal before puberty, there was a clear decrease during pubertal development (the Z-score change with age estimate 20.21 6 0.04, P , 0.001). In contrast, total bone CSA correspondingly increased (0.16 6 0.04, P , 0.001), which led to normal bone SSI (Table 3 ; Fig. 3 ). Partial volumeadjusted cortical vBMD slightly decreased before pubertal induction and increased thereafter (Fig. 3) . Therefore, there was no substantial change with age throughout the observation period (0.03 6 0.05, P = 0.54). Nevertheless, total bone CSA increased with age (0.13 6 0.04, P , 0.01), which was probably a consequence of the initial decrease in cortical vBMD, which led to a slight increase in bone SSI (0.10 6 0.03, P , 0.001; Fig. 3 ). Cortical thickness was normal (Table 3) , and no change with age was observed (20.01 6 0.03, P = 0.72).
The effects of hormonal treatment and fracture history on bone development in TS The forearm length Z-score increased with every year of estrogen substitution (b estimate 0.15 6 0.068, P = 0.029). The cortical vBMD Z-score was higher with longer GH treatment duration (b estimate 0.11 6 0.051, P = 0.035) and lower with a higher age at GH treatment commencement (b estimate 20.13 6 0.050, P = 0.016). A positive history of incident fractures was not significantly associated with any of the pQCT-derived bone parameters (data not shown). The FSH serum concentration at study end was negatively associated with SSI Z-score at the metaphysis (b estimate 20.01 6 0.01, P = 0.040) but not with any other pQCT bone measure.
Discussion
In this study, we show the controlled clinically significant fracture incidence and the longitudinal development of bone geometry and vBMD at the radius in a pediatric TS population using pQCT. We show that (1) fracture incidence in girls with TS treated with GH and substituted with estrogens is not higher compared with that in the healthy population, (2) trabecular vBMD was normal before puberty and decreased with age, but total bone CSA increased correspondingly and led to normal, estimated bone strength at the radial metaphysis, (3) cortical vBMD slightly decreased before puberty induction but increased thereafter, which together with an increase in total bone CSA, led to slightly increased, calculated bone strength at the radial diaphysis, and (4) a longer GH treatment duration was positively associated with a higher cortical vBMD.
The first study mentioning the fracture incidence in TS was published in 1991 (27) . The authors calculated that the annual incidence of fractures in girls with TS (aged 4 to 13 years) was not different from that in normal children younger than 15 years (19.9/100 vs 27.8/1000), but there was a substantially higher annual incidence of wrist fracture in TS (9.1/1000 vs 3.5/1000 in normal kids, P , 0.003). It is important to note that only 13/78 girls with TS from the study were treated either with estrogen (n = 13), GH (n = 12), and/or oxandrolone (n = 2) at a maximum duration of 6 months. In contrast, all of our study participants with TS were treated with GH, and all of those without spontaneous puberty were substituted with estrogens, which represents the current standard The estimated probabilities of a particular number of TS girls (out of 32) with incident fractures throughout the 6-year observation period based on the Monte Carlo simulation using the national data from control ageand sex-matched population.
care for these patients. We found that fractures of the long bones of the limbs (and vertebral fractures) are not more common among girls with TS compared with healthy controls. Therefore, we may speculate that current standard therapy can prevent bone fragility in TS. More importantly, the study by Ross et al. (27) also showed that areal BMD of the wrist (and spine) was not different between the girls with TS and healthy controls after adjusting for height/age and that the BMD was similar between the girls with TS, with and without a wrist fracture. In accordance with this study, we could not find decreased bone strength at the radius in TS in our study or any difference in bone strength between those who had and who had not sustained a fracture. One possible explanation is that common bone densitometry techniques (dual energy X-ray absorptiometry and pQCT) do not generate reliable parameters for fracture prediction, as was described earlier (28, 29) . However, factors other than bone quality can cause fractures in TS. In particular, we described low muscle power during a maximum voluntary, single two-leg jump test by mechanography (30) , which is a parameter partially influenced by muscle coordination and controlled by the central nervous system. Muscle power is thus a surrogate of visual-spatial cognitive function of the brain that has been shown to be impaired in TS (31) . Moreover, conductive hearing loss may be an additional reason for an increased fracture rate in TS (32) . All of these studies show that the fracture risk assessment in TS needs a multifactorial evaluation.
Normal trabecular vBMD before puberty and a decrease during and after pubertal development have been shown already in our initial cross-sectional study (11) . This is in accordance with previous observations of a normal size-adjusted lumbar spine areal BMD before puberty and a lack of adequate pubertal bone mass acquisition in TS girls (27, 33) . However, newer studies using pQCT showed normal trabecular vBMD in females with TS (10, 34) . We speculated that a different estrogen dose or formula could be the reason for the inconsistent findings (11) . Indeed, our girls used (on average) 1.2 mg of 17-b estradiol/day, whereas the participants in the study by Bechtold et al. (10) used estradiol valerate at 2.0 mg/day, and in the study by Holroyd et al. (34) , it was ethinyl-estradiol (the daily dose could not be calculated in this case). It seems that there might be an upper-dose limit beyond which there is no additional effect on the skeleton, which was represented by 17-b estradiol, 2 mg/day (35) . In contrast, the lower limit has not been studied yet. As regular and continuous estrogen replacement is needed to avoid osteoporosis and reduce increased fracture risk in TS (5, 36) , appropriate timing, dosing, and monitoring of estrogen substitution are crucial to improve the quality of life in TS patients. Cortical vBMD showed biphasic development when it decreased before pubertal induction and increased thereafter. Looking over the entire observation period, cortical vBMD was not significantly changed compared with the reference. This contradicts previous studies (10, 34) but is in line with our methodological paper (21) . Cortical vBMD is dependent on height (19) and cortical thickness (37) . We addressed both of these issues by calculating the heightspecific Z-scores and by adjusting cortical vBMD to partialvolume effect [related to thin cortices and described in Rittweger et al. (20) ]. These adjustments were not made in previous papers and are thus a possible reason for dissimilar findings. With the search for potential predictors, only GH treatment duration was significantly associated with cortical vBMD. This is in accordance with our initial crosssectional study and with papers on acromegaly (38) but not with studies of TS (39) . Whether this is a real causative relation or a coincidence still needs to be elucidated.
Interestingly, the total bone CSA at both radial sites increased, whereas trabecular vBMD (overall) and cortical vBMD (before pubertal induction) decreased, which might be understood as a physiological adaptation of the bone to withstand mechanical loads. Similar findings were shown by Bechtold et al. (10) . This process is especially effective during growth (40) . Indeed, the calculated bone SSI was normal at the metaphysis and slightly increased at the diaphysis in the girls with TS in our study. Even though trabecular vBMD remained low until postmenarcheal age in TS, cortical vBMD increased from previously low values. This could cause the difference in SSI between the two sites, as a larger bone that has been built already cannot be resorbed on the periosteal site. Normal bone strength in the girls with TS in our study would match with one of our most important findings-that the 6-year fracture incidence in girls with TS was not higher compared with the fracture rate in age-, country-, and time-matched healthy controls.
Limitations
It would be more appropriate to follow control girls of the same age compared with the girls with TS over the 6-year period to compare directly the fracture incidence between the groups. However, it would only be possible in a limited group of participants with a risk of selection bias. In contrast, our approach was to estimate the 6-year fracture incidence from the national data that were available. As we could not track individual data within the national registry, we estimated the 6-year fracture incidence as a maximum of 6 consecutive years for girls of the same age as the girls with TS. Therefore, it is very probable that the real fracture incidence is even higher in the normal population; thus, it is unlikely that the girls with TS in our study had a higher fracture rate compared with that in healthy girls.
Likewise, the development of pQCT-derived bone parameters was estimated from the change of Z-scores calculated from the cross-sectional normative dataset and was not based on parallel parameter tracking in individual controls. Nevertheless, reference data were obtained for the neighboring population with similar ethnicity and health, social, and environmental conditions. Thus, we believe that it is acceptable to assume that the two populations are interchangeable.
The results of this study are also limited by the age of the participants. We do not infer that the fracture risk is not increased in adults with TS despite the fact that it has been shown that long-term regular estrogen use prevents low BMD and osteoporosis in TS (36). Whether appropriate continuous estrogen substitution also leads to a reduction of fracture risk in adults with TS still needs to be elucidated.
Conclusions
This study shows that the 6-year fracture incidence is not increased among girls with TS who were treated with GH during growth and substituted with estrogens (when lacking spontaneous puberty) compared with that in normal girls. Even though trabecular vBMD decreased during puberty, total bone CSA increased and led to normal calculated bone SSI at the metaphysis of the radius, which supports the finding of a "common" fracture rate in TS.
